- Home
- CLLS vs OM Comparison
CLLS vs OM Comparison
Compare CLLS & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- OM
- Stock Information
- Founded
- CLLS 1999
- OM 2003
- Country
- CLLS France
- OM United States
- Employees
- CLLS N/A
- OM N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CLLS Health Care
- OM Health Care
- Exchange
- CLLS Nasdaq
- OM Nasdaq
- Market Cap
- CLLS 240.2M
- OM 31.8M
- IPO Year
- CLLS 2007
- OM 2020
- Fundamental
- Price
- CLLS $1.91
- OM $0.58
- Analyst Decision
- CLLS Buy
- OM Buy
- Analyst Count
- CLLS 2
- OM 6
- Target Price
- CLLS $8.00
- OM $4.42
- AVG Volume (30 Days)
- CLLS 25.4K
- OM 644.4K
- Earning Date
- CLLS 11-04-2024
- OM 11-05-2024
- Dividend Yield
- CLLS N/A
- OM N/A
- EPS Growth
- CLLS N/A
- OM N/A
- EPS
- CLLS N/A
- OM N/A
- Revenue
- CLLS $19,635,000.00
- OM $116,425,000.00
- Revenue This Year
- CLLS $271.02
- OM N/A
- Revenue Next Year
- CLLS $33.48
- OM $14.08
- P/E Ratio
- CLLS N/A
- OM N/A
- Revenue Growth
- CLLS N/A
- OM N/A
- 52 Week Low
- CLLS $0.96
- OM $0.44
- 52 Week High
- CLLS $3.77
- OM $6.37
- Technical
- Relative Strength Index (RSI)
- CLLS 36.61
- OM 40.13
- Support Level
- CLLS $1.95
- OM $0.59
- Resistance Level
- CLLS $2.06
- OM $0.65
- Average True Range (ATR)
- CLLS 0.10
- OM 0.06
- MACD
- CLLS -0.01
- OM 0.03
- Stochastic Oscillator
- CLLS 9.37
- OM 6.37
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.